



University of Dundee

Comparison of revision risks and complication rates between total HIP replacement and HIP resurfacing within the similar age group

Eethakota, Veera Venkata Satyanarayana; Vaishnav, Vinod; Johnston, Linda; Abboud, Rami; Wang, Weijie

Published in: Surgeon: Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland

DOI 10.1016/j.surge.2018.05.005

Publication date: 2018

Document Version Peer reviewed version

Link to publication in Discovery Research Portal

Citation for published version (APA):

Eethakota, V. V. S., Vaishnav, V., Johnston, L., Abboud, R., & Wang, W. (2018). Comparison of revision risks and complication rates between total HIP replacement and HIP resurfacing within the similar age group. *Surgeon: Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland*, *16*(6), 339-349. https://doi.org/10.1016/j.surge.2018.05.005

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.

You may not further distribute the material or use it for any profit-making activity or commercial gain.
You may freely distribute the URL identifying the publication in the public portal.

Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Title page (including author details)

© <2018>. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http:// creativecommons.org/licenses/by-nc-nd/4.0/ DOI 10.1016/j.surge.2018.05.005

COMPARISON OF REVISION RISKS AND COMPLICATION RATES BETWEEN TOTAL HIP REPLACEMENT AND HIP RESURFACING WITHIN THE SIMILAR AGE GROUP

Short title: Revision Risk for total hip replacement and resurfacing

Veera Venkata Satyanarayana Eethakota, Vinod Vaishnav, Linda Johnston, Rami Abboud, Weijie Wang^{*}

Department of Orthopaedic and Trauma Surgery, Ninewells Hospital and Medical School, TORT centre, University of Dundee, Dundee, United Kingdom

*Corresponding author: Dr Weijie Wang <u>w.wang@dundee.ac.uk</u> Phone: 0044 1382 383518 Department of Orthopaedic and Trauma Surgery, Institute of Motion Analysis and Research, Ninewells Hospital and Medical School, University of Dundee, DD1 9SY, UK

Acknowledgements

The authors are grateful to the Tayside Arthroplasty Audit Group, UK for the helps in the collection of data. The authors are grateful to Mr Ian Christen for editing the paper and Mr David Radily for data collection.

Abstract

Background and Purpose: Currently it is not clear whether age is a factor affecting revisions in total hip replacement (THR) and hip resurfacing (HR). This study aimed to investigate which of THR or HR is a higher risk in terms of revision and complication within similar age groups.

Methods: A systemic review was performed for published literature research databases and local data and compared the two procedures under the condition that both groups of patients were age matched. Meta-analysis techniques were used to analyse revision and complication rates. Twenty-seven literature studies were included along with local audit data. In total, 2520 HR procedures were compared with age-matched 2526 of THR procedures.

Main findings: It was found that revision risk of HR is significantly higher than THR (risk ratio 1.65, 95% CI 1.28-2.31, p<0.0001), highlighting that HR has a slightly higher chance of reoperation when compared to THR within the similar age group population. In terms of complications, HR was found to have an advantage over THR (risk ratio 0.84, 95% CI 0.73-0.96, p<0.01).

Conclusion: THR had a lower revision risk but a slightly higher complication risk than HR under the condition that the two surgical procedures were applied to similar age groups of patients. In other words, age has not played an important role in revision and complication. Survivorship cannot be measured as follow-up periods were different in the studies used.

Keywords: Total hip replacement, Hip resurfacing, Age, Revision, Risk ratio.

Introduction

Total hip replacement (THR) is the surgical procedure for treating end-stage arthritis of the hips and to enhance the quality of life in elderly patients, with a survivorship of 90% at 10 years.¹ In young males under 55 years of age, survivorship reduces to 80% at 10 years and may drop as low as 58% at 15 years.² Thus, revision surgery becomes vital. Sometimes, depending on patient age, multiple revisions may be required.

Hip resurfacing (HR) has now advanced as a substitute to THR and is thought to have the potential to resolve the issue of survivorship in young patients with a survivorship greater than 95% at five years and can increase to 98%.^{2, 3} The available literature is still inconsistent regarding rates of revision, incidences of complications, functional outcomes, patient satisfaction, and long-term results.^{4, 5} Despite numerous theoretical advantages over THR, HR has been associated with specific complications, for example, periprosthetic femoral neck fractures and metal particle issues, which has therefore caused surgeons confusion in regard to using it as the standard treatment method for younger patients.⁶ Given that many believe that THR is suitable for the older age group whilst HR is better for the younger age group, the research question is whether age is a factor affecting revision and complication rates. In most studies, the patient data is divided for the two surgical procedures with different age, and the outcomes and therefore cannot be compared. Therefore, if the patients are matched for age, the efficacy of HR could then be appreciated. Although the literature studies have investigated these two surgical modalities and assessed the evidence base with respect to their clinical, functional and radiological results, there has been little formal meta-analysis regarding the revision and complication risk of HR and THR from the comparative studies. Very few studies have compared these two procedures performed simultaneously and there is no study which has compared them for similar age groups.

To investigate whether the efficacy of one surgical procedure over the other, this current study employed meta-analysis to investigate the two procedures within similar age groups. To our best knowledge, such analysis has not been carried out before and will provide more accurate risk assessment of the procedures, and can compare HR and THR more comprehensively.

Materials and Methods

Search strategy. The primary search was done from the databases of the search engines, including PubMed Medline, ScienceDirect, Web of Science, Embase and Scopus. These were searched via Ovid using key terms "hip resurfacing compared to total hip replacement and/or arthroplasty", "revision rates of hip resurfacing and total hip replacement", "survivorship after hip resurfacing" and "results of hip resurfacing and total hip replacement". A secondary search was done from the reference list of relevant articles. Two authors carried out the selection of available articles.

Eligibility criteria. Using the obtained search results, relevant randomized controlled trials (RCTs) and observational studies (prospective and retrospective) were identified, which compared HR with THR. There was no language restriction in the search. There were no search specifications based on subject age, gender, preoperative diagnosis and type of prosthesis used. As the aim of the study was to look into specific factors like age group, the studies selected were where patient's mean age difference between two modalities (HR and THR) were 5 or <5 years. To avoid surgical and clinical bias, articles included were only those that compared the two surgical procedures in terms of revisions, complications, functional results and survivorship. Thus, inclusion criteria were as follows: HR and THR comparative studies, studies having patient's mean age difference 5/<5 years between HR and THR groups, and both procedures performed after the year 1990. The following studies were excluded: animal and cadaver studies, case reports, studies that report comparison outcomes of revision procedures, retrieval studies for failed implants, studies that compared either HR or THR with results of joint registries, meta-analysis, systematic reviews or editorial papers and studies which had either procedure performed before the year 1990. In total, 27 studies fitted all criteria (Figure 1).

[Figure 1]

Data extraction. Data were extracted from the included studies. The information collected was type of study (randomised, prospective or retrospective), patients' mean age, male and female ratio, average body mass index (BMI), number of patients in each cohort, time frame during which surgeries were performed, minimum follow-up, surgical approach used, type of prosthesis implanted, mean preoperative and postoperative Harris Hip Score (HHS), number of surgeons involved, number of complications, number of revisions with their reasons, and the overall survival. Another set of data was extracted from the xxxx (TAAG) database that was age and gender matched with all the same details as the studies from the literature. The TAAG database includes HR and THR surgeries performed during 2000-2014. TAAG data was analysed as one of the data sources parallel with the literature studies. The appropriate Caldicott ethical approval was obtained from the local University and NHS.

Primary outcome measure. The frequency of revision surgery due to any reason was the primary outcome measure.

Secondary outcomes measures. Included frequency of complications and preoperative and postoperative Harris Hip Score (HHS). Other outcome measures such as approach, duration of surgery, the length of hospital stay, radiological outcomes, quality of outcomes and immediate postoperative recovery status were not considered. All the complications (irrespective of their nature and time of occurrence) were grouped together for the outcome analysis.

Statistics. A meta-analysis was undertaken for the data extracted from the included studies and the local TAAG data. This was done using RevMan 5 software (version 5.3.5 Java 7 version for Mac OS X; The Nordic Cochrane Centre, Copenhagen, Denmark). IBM statistical package for social sciences (SPSS version 22) software was used to analyse the local data from the TAAG. Statistical heterogeneity was assessed with Chi^2 and I^2 tests. To assess any publication bias for the outcome measures, funnel plots were generated using the software RevMan 5, for revisions as well as for complications. The results of a comparable group were pooled using both the fixedeffect (Mantel-Haenszel test) and random-effect (DerSimonian and Laird method) models. Forest plots were created using the RevMan 5 software. A fixed-effect model was used for both the outcomes, as there was mild heterogeneity between studies for the outcomes of revision ($I^2=6\%$) and no heterogeneity between studies for the outcomes of complications ($I^2=0\%$). Mantel-Haenszel method was used to calculate risk ratio along with 95% confidence intervals (CI) for dichotomous data. For the outcomes, the current study used Risk Ratio (RR) as the summary static. RR was defined by the ratio of revision rates of HR to revision rates of THR. A revision rate was the ratio of the number of revision cases to the number of total cases. Similarly, the Risk Ratio for complications was the ratio of complication rates of HR to THR. In other words, if RR is larger than 1, HR has larger risk than THR, or vice versa. The p value <0.05 anywhere was considered significant.

Results

Cohort characteristics. From the 27 citations, 11 randomized controlled trials, 7 prospective and 9 retrospective studies were identified. The funnel plots revealed that no bias was present for the studies (Figures 2a and 2b). Altogether, there were 1862 HR procedures that were compared with 1899 THR procedures. From the local TAAG data, 658 HR were compared with age-matched 658 THR. In the included studies,⁷⁻³³ the mean age in the HR group was 51.3 years (SD 5.3) while the mean age in the THR

group was 52.8 years (SD 5.3). In the TAAG data, mean age was similar for the two groups 51.5 years (SD 8.3). In the included studies,⁷⁻³³ there were 1305 males and 516 females in the HR group. The THR group had 1240 males and 721 females. The TAAG data had 434 males and 224 females in the HR group, and 278 males and 380 females in the THR group. Twenty studies stated BMI, ⁷⁻³³ for which means were 27.1 (SD, 1.4) and 28.1 (SD, 1.5) in HR and THR group respectively. Means of BMI in TAAG data were 27.8 (SD, 4.2) and 28.9 (SD, 5.8) for the HR and THR group respectively (Table 1). The follow-up of various studies ranged from the minimum of 6 months to maximum of 120 months. The demographic characteristics of all the included studies are shown in Table 1 and Table 2.

[Figures 2a and 2b]

[Tables 1 and 2]

Different types of prosthesis were used in the included studies.⁷⁻³³ The most common systems used for HR were Durom hybrid resurfacing ¹⁰⁻¹⁶ followed by Conserve plus.^{7,9, 20, 23, 26, 30} For the THR group the variety of implants used are shown in Table 3. In the TAAG data, the most commonly used system for resurfacing was Birmingham Hip Resurfacing (BHR) in 96% of cases. The collared polished tapered (CPT) and Exeter prosthesis accounted for 43% of the THR implants used. The most common indication for surgery was osteoarthritis.

[Table 3]

Meta-analysis

Risk Ratio for Revision rates. Of the included 27 literature studies, eight studies had zero revisions in both HR and THR groups. ^{11, 13, 18-21, 23, 31} Since there was marginal heterogeneity between studies for the outcome of revisions ($I^2=5\%$), the fixed–effect model was used for the analysis. The pooled data, i.e. 27 literature studies and TAAG, showed a higher incidence of revision in the HR group than in the THR group with significant difference (RR, 1.65; 95% CI, 1.28-2.31; p<0.0001) and total revisions reaching 142 in the HR group and 86 in the THR group out of 2520 and 2556 cases respectively as seen in Figure 3. Moreover, when a random-effect model was used, the results were almost the same as the fixed-effect model (RR, 1.63; 95% CI, 1.20-2.20; p<0.002), favoured THR (Figure 4). With both the models (fixed-effect and random-effect), the overall effect remained significant (p<0.0001 and p<0.002) and the overall outcome favoured THR.

[Figs 3-4]

Risk Ratio for Complication rates. The complications were described in 22 literature studies and in the TAAG data. Five studies did not report complication rates.^{13, 15-16, 23, 31} As there was no heterogeneity between studies for the outcome of complications ($I^2=0$), the fixed-effect model was used for the analysis. The overall complication risk in the literature studies and TAAG data was significant (RR, 0.84; 95% CI, 0.73-0.96; p<0.01) as seen in Figure 5. The causes of revisions for both HR and THR are described in Table 4 and Figure 6. The study by Stulberg et al (2009) had the maximum weight (34.9%), followed by local TAAG data (34.3%).²² As the complication information was not fully reported by the literature studies, we report the complication details from TAAG only for reference. In the TAAG data, there were 86 complications for HR and 112

complications for THR (Table 5 and Figure 7). Other complications were systemic such as anaemia, pyrexia, postoperative hypotension, pressure sores etc. (encountered in both groups). It is not clear whether these complications were responsible for the revisions.

[Tables 4-5]

[Figures 5-7]

Discussion

The main findings of this study are that HR has a higher risk of revision when compared to THR (p<0.001) within the similar age groups. Regarding complications, HR had a lower ratio than THR (p<0.01). High rates of revision in HR could be related to many factors such as surgeon's experience, inappropriate patient and implant selection, but not to age. Currently, there is a lack of availability of long-term data on the modern HR designs. Still there is a lack of evidence to prove the clinical and functional superiority of HR over THR, but HR can provide similar functional results to THR, under experienced surgeon in a carefully selected patient in terms of age, gender and prosthesis design.

Revision rates described in early studies were poor with HR and related to factors such as early wear, osteolysis, and component loosening.³⁴ Whereas in another meta-analysis by Smith et al, HR had twice the revision risk as compared to THR.³⁵ A systemic review by Deborah et al ³⁶ showed that revision rates are more frequent and early in HR when compared to THR. In all these studies, age has not been considered as a specific factor. Of the 27 included studies, five studies projected higher revisions risk in THR group as compared to HR group, ^{9, 16, 28-29, 32} eight studies could not estimate revision risks as there were no revisions in each group and 11 studies favoured THR by showing higher revision risk in HR. Three studies ^{7, 30, 33} showed exact equal revision rates with both procedures. Therefore, the current study, based on available literature and local data, provides relatively reliable evidence that HR is higher in revision than THR within similar age groups.

The current study also indicated that there may be an association between the type of prosthesis used and revision rates in the HR group. Seven of the included studies ¹⁰⁻¹⁶ used the Durom system, of which four had higher revisions for HR,^{10, 12, 14-15} one study showed THR with higher risk ¹⁶ and the other two studies could not estimate the revision risk ^{11, 13}. Although the contributors to the failure of HR are multifactorial, component design, geometry, and acetabular component orientation could be the most important factors.

The current study also demonstrated that the complication risk in HR was better than THR (p<0.01). Nearly half of the described studies had high proportions of complications for THR as compared to HR. However, it was unclear what proportion of these complications were converted into revisions. Some of the complications, such as acute dislocation, sciatic nerve palsy, squeaking and trochanteric bursitis, were treated by re-operations rather than revising the existing components. Re-operations are a different entity from revisions and it was not known what proportion of these complications were actually revised or re-operated. In the TAAG data, the most common complications included infection (both deep and superficial), aseptic loosening and metallosis, accounting for approximately 75% of all complications. The revisions include to these three complications comprised approximately 70% of all the revisions.

the THR group, common complications were infections (deep and superficial), periprosthetic fractures and aseptic loosening, which accounted for approximately 57% of all the complications and these were responsible for approximately 71% of the total revisions in the THR group. Marshall et al ³⁷ concluded that revisions and reoperations were more frequent and occurred earlier with HR except when discontinued devices were removed from the analysis. Conversely, dislocations were more frequent with THR.

Strength and weaknesses. The strength of the current study is that it considered those comparative studies which had these procedures with similar mean age group, thereby minimising the surgical bias, which is the important key factor for the outcome of these procedures. Secondly, as HR had earlier poor results and unacceptably high rates of failures, it was taken into account only those studies that had these surgeries performed after the year 1990 when modern HR designs were first used. The strict selection criteria make this study unique. The study had a few limitations. Firstly, the included studies had inadequate length of follow-up, which are deficient in long-term follow-up data for modern HR when compared to conventional THR procedures. So, therefore no survivorship analysis was possible. Secondly, the included studies were not implant (prosthesis) specific. Thirdly, there could be a bias in revision risk, and it was not clear from available data what ratio of complications were converted to revisions. Finally, some of the included studies were operated by multi-level surgeons, which could affect the final outcome.

From the current study, it is still unclear regarding the superiority of one procedure over another. We can undoubtedly state that there is still argument and scope for further research on this topic. We need to review more isolated long-term randomized, prospective trials that will have a high level of evidence to the final outcome of the research. Moreover, research should also focus on other aspects such as surgical techniques, specific implant designs, and metallurgy.

Conclusion

The findings of the current study indicate that the revision risk of HR is significantly higher than THR within similar age group population. Literature studies have not reported this conclusion using age-matched data. In terms of complications, HR is found to have the advantage in comparison with THR. Survivorship cannot be measured as the follow-up periods were different in the studies used.

Compliance with Ethical Standards

Conflict of Interest: The authors declare that they have no conflict of interest.

Funding: There is no funding source.

Ethical approval: This article does not contain any studies with human participants or animals performed by any of the authors. This study was approved by the local ethics research committee.

References

1. Learmonth I, Young C, Rorabeck C. The operation of the century: total hip replacement. *Lancet* 2007; 370: 1508–1519.

2. Matharu G, McBryde C, Pynsent W, Pynsent P, Treacy R. The outcome of the Birmingham hip resurfacing in patients aged < 50 years up to 14 years post- operatively. *Bone Joint J* 2013; 95-B: 1172–1177.

3. Rahman L, Muirhead-Allwood S, Alkinj M. What is the midterm survivorship and function after hip resurfacing? *Clin Orthop Relat Res* 2010; 468: 3221–3227.

4. Malviya A, Stafford G, Villar RJ, Villar R. Have the media influenced the use of hip resurfacing arthroplasty? A review of UK prints media. *Ann R Coll Surg Engl* 2012; 94: 432–43.

5. Villar R. Resurfacing arthroplasty of the hip. J Bone Joint Surg [Br] 2004; 86-B: 157-158.

6. Macpherson G, Breusch S. Metal-on-metal hip resurfacing: a critical review. *Arch Orthop Trauma Surg* 2011; 131: 101–110.

7.Bisseling P, Smolders J, Hol A, van Susante J. Metal ion levels and functional results following resurfacing hip arthroplasty versus conventional small-diameter metal- on-metal total hip arthroplasty: a 3 to 5-year follow-up of a randomized controlled trial. *J Arthroplasty* 2015; 30: 61–67.

8.Gustafson K, Jakobsen SS, Lorenzen ND, Thyssen JP, Johansen JD, Bonefeld CM, Stilling M, Baad-Hansen T, Soballe K. Metal release and metal allergy after total hip replacement with resurfacing versus conventional hybrid prosthesis. *Acta Orthopaedica* 2014; 85(4): 348-354.

9. Smolders JMH, Pakvis D, Hendrickx B, Verdonschot N, Susante V. Periacetabular Bone Mineral Density Changes after Resurfacing Hip Arthroplasty versus Conventional Total Hip Arthroplasty. A Randomized Controlled DEXA Study. *The Journal of Arthroplasty* 2013;28: 1177–1184.

10. Vendittoli P, Riviere C, Roy A, Barry J, Lusignan D, Lavigne M. Metal-on- metal hip resurfacing compared with 28-mm diameter metal-on-metal total hip replacement: A randomized study with six to nine years' follow-up. *Bone Joint J* 2013; 95-B: 1464–73.

11. Lavigne M, Therrien M, Nantel J, Roy A, Prince F, Vendittoli P. The John Charnley Award-The functional outcome of hip resurfacing and large-head THA is the same: A randomized, double-blind study. *Clin Orthop Relat Res* 2010; 468: 326–336.

12. Vendittoli P, Roy A, Mottard S, Girard J, Lusignan D, Lavigne M. Metal ion release from bearing wear and corrosion with 28 mm and large-diameter metal-on-metal bearing articulations. *J Bone Joint Surg [Br]* 2010; 92-B: 12-19.

13. Garbuz DS, Greidanus N, Masri B, Duncan C. Metal-on-Metal Hip Resurfacing versus Large-diameter Head Metal-on-Metal Total Hip Arthroplasty. *Clin Orthop Relat Res* 2010; 468: 318–325.

14. Rama K, Vendittoli P, Ganapathi M, Borgmann R, Roy A, Lavigne M. Heterotopic ossification after surface replacement arthroplasty and total hip arthroplasty: A randomized study. *J Arthroplasty* 2009; 24(2): 256-262.

15. Lavigne M, Masse V, Girard J, Roy AG, Vendittoli P. Return to sport after hip resurfacing or total hip arthroplasty: A prospective randomized study. *Rev Chir Orthop* 2008; 94: 361-367.

16. Girard J, Lavigne M, Vendittoli P, Roy A. Biomechanical reconstruction of the hip: a randomised study comparing total hip resurfacing and total hip arthroplasty. *J Bone Joint Surg* [*Br*] 2006; 88-B: 721-6.

17. Howie D, McGee M, Costi K, Graves S. Metal-on-metal resurfacing versus total hip replacement- the value of a randomized clinical trial. *Orthop Clin N Am* 2005; 36: 195-201.

18. Fink Barnes L, Johnson L, Patrick Jr D, Macaulay W. Metal-on-metal hip resurfacing compared with total hip arthroplasty: two to five year outcomes in men younger than sixty-five years. *International Orthopaedics (SICOT)* 2014; 38: 2435–2440.

19. Costa ML, Achten J, Parsons N, Edlin R, Foguet P, Prakash U, Griffin D. Total hip arthroplasty versus resurfacing arthroplasty in the treatment of patients with arthritis of the hip joint: single centre, parallel group, assessor blinded, randomized controlled trial. *British Medical J* 2012; 344: e2147.

20. Wang Q, Zhang S, Chen Y, Shen H, Shao J. Resurfacing arthroplasty for hip dysplasia: A prospective randomized study. *J Bone Joint Surg [Br]* 2012; 94-B: 768–773.

21. Sandiford N, Muirhead-Allwood S, Skinner J, Hua J. Metal on metal hip resurfacing versus uncemented custom total hip replacement – early results. Journal of Orthopaedic *Surgery and Research* 2010; 5: 88.

22. Stulberg B, Trier K, Naughton M, Zadzilka J. Results and Lessons Learned from a United States Hip Resurfacing Investigational Device Exemption Trial. *J Bone Joint Surg Am* 2009; 90 Suppl 3: 21-26.

23. Zywiel M, Marker D, McGrath M, Delanois R, Mont M. Resurfacing Matched to Standard Total HipArthroplasty by Preoperative Activity Levels a Comparison of Postoperative Outcomes. *Bulletin of the NYU Hospital for Joint Diseases* 2009; 67(2):116-119.

24. Mont M, Rajadhyksha A, Hungerford D. Outcomes of limited femoral resurfacing arthroplasty compared with total hip arthroplasty for osteonecrosis of the femoral head. *J Arthroplasty* 2001; 16(8): 134-139.

25. Parry M, Povey J, Blom A, Whitehouse M. Comparison of acetabular bone resection, offset, leg length and postoperative function between hip resurfacing arthroplasty and total hip arthroplasty. *The Journal of Arthroplasty* 2015; 30: 1799–1803.

26. Arndt J, Wera G, Goldberg V. An initial experience with hip resurfacing versus cementless total hip arthroplasty. *HSSJ* 2013; 9: 145–149.

27. Issa K, Palich A, Tatevossian T, Kapadia B, Naziri Q. Mont M. The outcomes of hip resurfacing compared to standard primary total hip arthroplasty in Men. *BMC Musculoskeletal Disorders* 2013; 14: 161.

28. Costa CR, Jhonson A, Naziri Q, Mont M. The outcomes of Cormet[™] hip resurfacing compared to standard primary total hip arthroplasty. *Bulletin of the NYU Hospital for Joint Diseases* 2011; 69 (1): S12-15.

29. Baker R, Pollard T, Eastaugh-Waring H, Bannister G. A medium-term comparison of hybrid hip replacement and Birmingham hip resurfacing in active young patients. *J Bone Joint Surg [Br]* 2011; 93-B: 158-63.

30. Mont M, Marker D, Smith J, Ulrich S, McGrath M. Resurfacing is comparable to total hip arthroplasty at short-term follow-up. *Clin Orthop Relat Res* 2009; 467: 66–71.

31. Patel R, Stygall J, Harrington J, Newman S, Haddad F. Intra-operative cerebral microembolisation during primary hybrid total hip arthroplasty compared with primary hip resurfacing. *Acta Orthop. Belgica* 2009; 75: 671-677.

32. Hall D, Srikantharajah D, Anakwe R, Gaston P, Howie C. Patient-reported outcomes following metal-on-metal resurfacing of the hip and total hip replacement. *Hip Int* 2009; 19(3): 245-50.

33. Pollard T, Baker R, Eastaugh-Waring S, Bannister G. Treatment of the young active patient with osteoarthritis of the hip: A five- to seven-year comparison of hybrid total hip arthroplasty and metal-on-metal resurfacing. *J Bone Joint Surg [Br]* 2006; 88-B: 592-600.

34. Amstutz H, Duff M. Background of metal-on-metal resurfacing. Proceedings of the institution of mechanical engineers, Part H. *Journal of Engineering in Medicine* 2006; 220: 85.

35. Smith T, Nichols R, Donell S, Hing C. The clinical and radiological outcomes of hip resurfacing versus total hip arthroplasty: a meta-analysis and systematic review. *Acta Orthopaedica* 2010; 81(6): 684-695.

36. Deborah A, Pykerman K, Werle J, Lorenzetti D, Wasylak T, Noseworthy, Dick D, Greg O'Connor, Sundaram A, Heintzbergen S, Frank C. Hip Resurfacing versus Total Hip Arthroplasty: A Systematic Review Comparing Standardized Outcomes. *Clin Orthop Relat Res* 2014; 472: 2217–2230.

37. Marshall D, Pykerman K, Werle J, Lorenzetti D, Wasylak T, Noseworthy T, Dick D, Connor G, Sundaram A Heintzbergen S, Frank C. Hip resurfacing versus total hip arthroplasty: A systematic review comparing standardized outcomes. *Clin Orthop Relat Res* 2014; 472: 2217–2230.

Figure captions

Figure 1. Preferred reporting items for systematic reviews and meta-analysis (PRISMA) flow chart.

Figure 2. Funnel plots showing rare publication bias for a frequency of revision surgery on the left (2.a) and no publication bias for a frequency of complications on the right (2.b). Note: Each dot represents a study/data source used; the vertical-axis shows study precision and the horizontal-axis gives the study's result. A symmetric inverted funnel shape means a 'good-quality' data set, in which publication bias is unlikely.

Figure 3. Forest plot to illustrate the difference in frequency of revision surgery between HR and THR using fixed-effect model.

Note: Forest plot shows risk ratios for each study (the point being the value and the line being associated confidence intervals), and the vertical line represents no effect. As risk ratio is calculated by HR/THR, and thus a value > 1 means that HR has higher risk than THR in revision.

Figure 4. Forest plot to illustrate the difference in frequency of revision surgery between HR and THR using random-effect model.

Note: The random-effect model is used to analyse data with bias. We use this model to double check the results from Figure 3 where a fixed-effect model was used. The results shows that both models gave similar results.

Figure 5. Forest plot to illustrate the difference in frequency of complications between HR and THR.

Note: As risk ratio is calculated by HR/THR, and thus a value > 1 means that HR has higher risk than THR in complication.

Figure 6. Proportion of complications in HR and THR in TAAG data. Note: The results are displayed as clinical reference rather than statistical comparison

Figure 7. The reasons for revisions in HR and THR in both Literature studies and TAAG data.

Note: The results are displayed as clinical reference rather than statistical comparison

	Literature Stud	lies	TAAG Data		
Characteristics	HR Studies	THR Studies	HR	THR	
No. of studies	27	27			
Total No. of hips	1862	1899	658	658	
Gender M/F	1305/516	1240/721	434/224	278/380	
Mean age, yrs (SD; range)	51.3 (5.3;34-64)	52.8 (5.3;35-64)	51.5 (8.3;21-75)	51.5 (8.3;21-75)	
Mean BMI (kg/m ²) (SD; range)	27.1 (1.4;23.5-29)	28.1 (1.5;23.3-30)	27.8 (4.2;12.8-42.1)	28.9 (5.8;11.1-64.9)	
Mean pre-op HHS, months (SD)	50.0 (6.85)	47.7 (6.37)	48.9 (11.5)	43.6 (10.9)	
Mean post-op HHS, months (SD)	93.0 (3.89)	92.80 (4.5)	94.5 (9.8)	87.7 (11.4)	
Diagnosis					
Osteoarthritis	1333	1256	575	501	
Dysplastic Hip	90	80	38	21	
Osteonecrosis	119	128	12	54	
Post-traumatic arthritis	19	20	7	6	
Ankylosing Spondylitis	0	0	6	6	
Perthes' Disease	0	0	5	15	
Rheumatoid Arthritis	19	20	1	24	
Others	0	0	14	32	
Not recorded	282	395	0	0	
Surgical approach					
Posterior	1151 (16)	888(15)	636	206	
Anterolateral	237 (4)	237 (4)	12	395	
Lateral	0	0	9	27	
Posterolateral	76 (2)	176 (3)	0	29	
Not recorded	398 (5)	598 (5)	1	1	
No. of complications	198	203	86	112	
No. of revisions	77	45	65	41	

Table 1. Demographic characteristics of the Literature studies and TAAG data

Note: SD: standard deviation; HHS; Harris Hip Score; TAAG is local data used as one of data sources in meta-analysis.

Randomized controlled trials	No. of hips	Males / Females	Mean age (years)	Mean BMI (kg/m²)	Duration of Surgeries	Min. follow-up (months)
Bisseling et al ⁷	HR-38	21/17	57.5	26.1	2007-2010	36
Disselling et al	THR-33	21/12	59.2	28	2007-2010	36
Gustafson et al ⁸	HR-19	9/10	64	26	2005-2007	60
Oustaison et al	THR-25	7/18	64	27	2005-2007	60
Smolders et al ⁹	HR-38	21/17	57.5	26.1	2007-2010	24
Children of al	THR-34	21/13	59.1	28	2007-2010	24
Vendittoli et al ¹⁰	HR-109	69/40	49.2	27	2003-2006	96
	THR-100	68/32	51	30	2003-2006	96
Lavigne et al ¹¹	HR-24	14/10	49.6	27.9	2006-2007	12
	THR-24	15/9	49.8	27.8	2006-2007	12
Vendittoli et al ¹²	HR-64	42/22	49	27.1	2003-2006	24
	THR-53	33/20	51	29.2	2003-2006	24
Garbuz et al 13	HR-48	45/3	51.5	28.3	2005-2008	12
	THR-56	50/6	52	28.2	2005-2008	12
Rama et al ¹⁴	HR-56	65/38	50	27.3	2003-2005	12
	THR-97 HR-81	66/31 53/28	50	29.7	2003-2005	12
Lavigne et al ¹⁵	-	53/28 51/20	48.4	27 28.7	-	27 27
-	THR-71 HR-49	31/18	50 47	28.7	- 2003-2005	12
Girard et al ¹⁶	THR-55	31/18	47	27.3	2003-2005	12
	HR-11		46	-		
Howie et al ¹⁷	THR-13	6/5 9/4	40 50	-	1993-1995 1993-1995	101 101
Prospective stud		3/4	50	-	1990-1990	101
Fink Barnes et	HR-89	80/0	52.7	28.6	2006-2010	24
al ¹⁸	THR-47	43/0	57.4	30.3	2006-2010	24
Costa ML et al ¹⁹	HR-60	38/22	56.3	28.6	2007-2010	12
	THR-66	36/30	56.6	28.7	2007-2010	12
Wang et al ²⁰	HR-37	5/29	45.7	23.5	2005-2006	59.4
0	THR-39	9/29	46.5	23.3	2005-2006	60.6
Sandiford et al ²¹	HR-141	93/44	55.3	26	2000-2002	19.2
	THR-141	75/59	53.9	26	2000-2002	13.4
Stulberg et al ²²	HR-337	228/109	50	-	2001-2003	24
	THR-266	165/101	53	-	2001-2003	24
Zywiel et al 23	HR-33	23/10	53	28	2002-2005	42
	THR-33	23/10	53	29	2002-2005	42
Mont et al ²⁴	HR-30	18/12	34	-	1992-1996	84
	THR-30	18/12	35	-	1992-1996	90
Retrospective st	udies					
Parry et al ²⁵	HR-87	79/8	53	-	2004-2010	72
	THR-89	34/55	58	-	2004-2010	60
Arndt et al ²⁶	HR-55	38/17	49.6	-	2002-2005	48.6
	THR-100	74/26	56.5	-	1997-2001	56.8
Issa et al ²⁷	HR-120	114/0	50	28.2	2007-2009	40
0 (00 : 28	THR-120	117/0	53	28.7	2007-2009	40
Costa CR et al ²⁸	HR-73	63/4	51	28	2007-2009	30
Dalaan (1 ²⁹	THR-137	65/60	54	28	2007-2009	30
Baker et al ²⁹	HR-63	40/11	49.8	25.7	1999-2001	108
Mont et =130	THR-54	40/13	50.4	27	1996-2001	108
Mont et al ³⁰	HR-54	36/18	55	29	2002-2005	39
Patel et al ³¹	THR-54	36/18	55	29	2002-2005	39
Patel et al	HR-12	9/3	55.9	-	-	24
Holl at al ³²	THR-12	9/3	57.8	1		24
Hall et al ³²	HR-33	27/6	53.7	-	2006-2007	6
i iali et al	THR-99	81/18	55.3	-	2006-2007	6 61
		40/40				- m 1
Pollard et al ³³	HR-54	40/13	50	25.7	1999-2001	
		40/13 40/11 434/224	50 50 51.5	25.7 27 27.8	1999-2001 1996-2001 2001-2011	80 120

Table 2. Demographic characteristics of the Randomized controlled trials and selected data sources

Note: Selected studies have similar age groups in THR and HR; Follow-up are different.

-		1
HR prosthesis type	No. of patients (No. of literature studies) using the implant (n=1862)	No. of patients using the implant in TAAG data (n=658)
Birmingham Hip Resurfacing system (Smith and Nephew, Warwick UK)	380 (4)	-
BHR-Midland Technologies, UK	66 (2)	622
Conserve Plus (Wright Medical Technology, Arlington, TN)	255 (6)	-
Durom hybrid resurfacing system (Zimmer, Warsaw, IN)	478 (7)	34
Cormet MoM (Corin, UK)	530 (3)	-
Stemless resurfacing system (Depuy, Warsaw, IND)	30 (1)	-
McMinn acetabular and mini stemmed McMinn femoral resurfacing component (Corin Medical Ltd, UK)	11 (1)	-
Recap Femoral Resurfacing System (Biomet,UK)	19 (1)	-
Mitch TRH (Stryker)	0 (0)	2
Not stated	93(2)	-
THR prosthesis type	No. of patients (No. of literature studies) using the implant	No. of patients using the implant in TAAG data
Zweymuller Classic (Zimmer)	67(2)	-
CLS Spotorno (Zimmer)	232(3)	54
CPT (Zimmer)	145(3)	188
VERSYS FMT (Zimmer)	100(1)	-
M/L Taper (ZIMMER)	56(1)	31
Exeter (Howmedica, Stryker)	92(3)	92
E-series (Stryker)	90(1)	-
Accolade (Stryker)	290(3)	10
SL Plus (Stryker)	39(1)	-
ABG I and II (Stryker) Aesculap (Aesculap)	266(3)	15 17
Biomet (Biomet)	-	1
Summit and Pinnacle (Depuy)	89(1)	-
Corail pinnacle (Depuy)	141(1)	1
Charnley (Depuy)	-	51
Lubinus (LINK)	-	23
Mayo (Zimmer)	-	64
Polarstem (Smith and Nephew)	-	1
Profemur (Wright Medial)	-	1
	-	1
S-ROM (Depuy)		
S-ROM (Depuy) Spectron (Smith and Nephew)	12(1)	3
	12(1) -	3 96

Reason for Revision	No of revision studies (% of total re	ons in Literature visions)	No revisions in TAAG data (% of total revisions)	
	HR	THR	HR	THR
Aseptic loosening of acetabulum/ femur	39 (50.6%)	15 (33.3%)	22 (33.8%)	8 (19.5%)
Infection	3 (3.9%)	8 (17.7%)	4 (6.1%)	4 (9.7%)
Peri-prosthetic fracture	19 (24.6%)	8 (17.7%)	5 (7.6%)	5 (12.2%)
Dislocation	3 (3.9%)	12 (26.6%)	3 (4.6%)	8 (19.5%)
Unexplained pain	3 (3.9%)	2 (4.4%)	11 (16.9%)	6 (14.6%)
Metallosis	6 (7.7%)	-	18 (27.6%)	10 (24.3%)
Avascular necrosis of femoral head	4 (5.1%)	-	2 (3%)	-
Total Revisions	77	45	65	41

Table 4. Reasons for revision in HR and THR in both Literature studies and TAAG data

Table 5. Common complications in the two groups of TAAG data

Complication	No of HR cases	No of THR cases
Superficial infection	13	21
Deep infection	5	17
Loose acetabulum/ femur	16	8
Peri-prosthetic fracture	5	18
Dislocation	4	13
Deep Vein Thrombus (DVT)	2	4
Metallosis	17	6
Sciatic Nerve palsy	3	5
Others (pyrexia, UTI, chest infections etc.,)	21	20

Figure 1 Click here to download high resolution image




Figure 2a Click here to download high resolution image





Figure 2b Click here to download high resolution image



Study or Subgroup Ardnt et al 2013 Baker et al 2011 Bisseling et al 2015 Costa CR et al 2011 Costa ML et al 2012	Events 8 5	Total 55	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Baker et al 2011 Bisseling et al 2015 Costa CR et al 2011	5		4			m-n, rikeu, 33% ci	m n, rived, somet
Bisseling et al 2015 Costa CR et al 2011			4	100	3.2%	3.64 [1.15, 11.53]	
Costa CR et al 2011	1	63	9	54	11.1%	0.48 [0.17, 1.34]	
	3	38	3	33	3.7%	0.87 [0.19, 4.01]	
Costa ML et al 2012	0	73	3	137	2.8%	0.27 [0.01, 5.09]	
	0	60	0	66		Not estimable	
Fink Barnes et al 2014	0	89	0	47		Not estimable	
Garbuz et al 2010	0	48	0	56		Not estimable	
Girard et al 2006	0	49	1	55	1.6%	0.37 [0.02, 8.96]	
Gustafson et al 2014	1	19	0	25	0.5%	3.90 [0.17, 90.74]	
Hall et al 2009	1	33	2	99	1.1%		· · · · · · · · · · · · · · · · · · ·
Howie et al 2005	8	11	2	13	2.1%	4.73 [1.26, 17.79]	
ssa et al 2013	2	120	1	120	1.1%		
Lavigne et al 2008	1	81	0	71	0.6%	2.63 [0.11, 63.65]	
Lavigne et al 2010	0	24	0	24		Not estimable	
Mont et al 2001	3	30	2	30	2.3%	1.50 [0.27, 8.34]	
Mont et al 2009	2	54	2	54	2.3%	1.00 [0.15, 6.84]	
Parry et al 2015	4	87	1	89	1.1%		0 - 6 - 6
Patel et al 2009	0	12	0	12		Not estimable	
Pollard et al 2006	4	54	4	51	4.7%	0.94 [0.25, 3.58]	1
Rama et al 2009	2	103	0	97	0.6%		
Sandiford et al 2010	0	141		141		Not estimable	
Smolders et al 2013	1	38	0 2	33	2.4%	0.43 [0.04, 4.57]	
Stulberg et al 2009	24	337	5	266	6.4%	3.79 [1.47, 9.80]	· · · · · · · · · · · · · · · · · · ·
TAAG data	65	658	41	658	46.9%	1.59 [1.09, 2.31]	
endittoli et al 2010	2	64	0	53	0.6%	4.15 [0.20, 84.68]	
/endittoli et al 2013	6	109	4	100	4.8%	1.38 [0.40, 4.74]	
Wang et al 2012	0	37	0	39		Not estimable	
Zywiel et al 2009	0	33	0	33		Not estimable	
Total (95% CI)		2520		2556	100.0%	1.65 [1.28, 2.13]	•
Total events	142		86				25.5
Heterogeneity. Chi ² = 19.9	94, df = 1	9(P = 0	$(40); 1^2 = 5\%$				0.01 0.1 1 10

Total 55 63 38 73 60 89 48 49 19 33 11 120	4 9 3 0 0 1 0	Total 100 54 33 137 66 47 56 55	6.4% 7.9% 3.8% 1.0%	0.48 [0.17, 1.34] 0.87 [0.19, 4.01]	M-H, Random, 95% Cl
63 38 73 60 89 48 49 19 33 11	9 3 0 0 1 0	54 33 137 66 47 56	7.9% 3.8% 1.0%	0.48 [0.17, 1.34] 0.87 [0.19, 4.01] 0.27 [0.01, 5.09] Not estimable Not estimable	
38 73 60 89 48 49 19 33 11	3 0 0 1 0	33 137 66 47 56	3.8% 1.0%	0.87 [0.19, 4.01] 0.27 [0.01, 5.09] Not estimable Not estimable	
73 60 89 48 49 19 33 11	3 0 0 1 0	137 66 47 56	1.0%	0.27 [0.01, 5.09] Not estimable Not estimable	
60 89 48 49 19 33 11	0 0 1 0	66 47 56		Not estimable Not estimable	
89 48 49 19 33 11	0 0 1 0	47 56		Not estimable	
48 49 19 33 11	0 1 0	56			
49 19 33 11	1			Not estimable	1
19 33 11	0	55			
33 11			0.9%	0.37 [0.02, 8.96]	() () () () () () () () () () () () () (
11		25	0.9%	3.90 [0.17, 90.74]	
	2	99	1.6%	1.50 [0.14, 16.01]	
120	2	13	5.0%	4.73 [1.26, 17.79]	
	1	120	1.6%	2.00 [0.18, 21.76]	
81	0	71	0.9%	2.63 [0.11, 63.65]	
24	0	24		Not estimable	
30	2	30	3.0%	1.50 [0.27, 8.34]	
54	2	54	2.4%	1.00 [0.15, 6.84]	
87	1	89	1.9%	4.09 [0.47, 35.88]	
12	0	12		Not estimable	
54	4	51	4.9%	0.94 [0.25, 3.58]	
103	0	97	1.0%	4.71 [0.23, 96.91]	
141	0	141		Not estimable	1.1
38	2	33	1.6%	0.43 [0.04, 4.57]	2
337	5	266	9.2%	3.79 [1.47, 9.80]	
658	41	658	39.3%	1.59 [1.09, 2.31]	
64	0	53	1.0%	4.15 [0.20, 84.68]	
109	4	100	5.7%	1.38 [0.40, 4.74]	
37	0	39		Not estimable	
33	0	33		Not estimable	
2520		2556	100.0%	1.63 [1.20, 2.20]	*
	86				102.5
2	37 33 520 94,	37 0 33 0 520 86	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	37 0 39 Not estimable 33 0 33 Not estimable 520 2556 100.0% 1.63 [1.20, 2.20] 86 94, df = 19 (P = 0.40); l ² = 5% 5% 5

	Hip resur	Hip resurfacing Total Hip Replace		cement		Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI	
Ardnt et al 2013	8	55	10	100	2.2%	1.45 [0.61, 3.47]		
Baker et al 2011	3	63	9	54	3.0%	0.29 [0.08, 1.00]	2 <u></u>	
Bisseling et al 2015	1	38		33	1.0%	0.29 [0.03, 2.65]		
Costa CR et al 2011	1	73	3	137	0.6%	0.63 [0.07, 5.91]		
Costa ML et al 2012	11	60		66	5.2%	0.67 [0.35, 1.31]		
Fink Barnes et al 2014	6	89	2	47	0.8%	1.58 [0.33, 7.55]	· · · · · · · · · · · · · · · · · · ·	
Garbuz et al 2010	0	48	0	56		Not estimable		
Girard et al 2006	0	49	0	55		Not estimable		
Gustafson et al 2014	1	19		25	0.1%	3.90 [0.17, 90.74]		
Hall et al 2009	0	33	1	99	0.2%	0.98 [0.04, 23.50]		
Howie et al 2005	8	11		13	0.8%	3.15 [1.10, 9.06]		
Issa et al 2013	1	120	1	120	0.3%	1.00 [0.06, 15.80]		
Lavigne et al 2008	0	81		71		Not estimable		
Lavigne et al 2010	2	24	3	24	0.9%	0.67 [0.12, 3.64]		
Mont et al 2001	0	30		30	0.5%	0.33 [0.01, 7.87] -		
Mont et al 2009	1	54	1	54	0.3%	1.00 [0.06, 15.58]		
Parry et al 2015	4	87	2	89	0.6%	2.05 [0.38, 10.88]		
Patel et al 2009	0	12	0	12		Not estimable		
Pollard et al 2006	7	54	5	51	1.6%	1.32 [0.45, 3.90]		
Rama et al 2009	0	103		97	1.1%	0.13 [0.01, 2.57] +		
Sandiford et al 2010	5	141		141	1.2%	1.25 [0.34, 4.56]		
Smolders et al 2013	1	38		33	0.7%	0.43 [0.04, 4.57]		
Stulberg et al 2009	115	337		266	34.9%	0.89 [0.72, 1.10]	-	
TAAG data	86	658	112	658	34.3%	0.77 [0.59, 1.00]		
Vendittoli et al 2010	2	64		53	0.2%	4.15 [0.20, 84.68]		
Vendittoli et al 2013	20	109	29	100	9.3%	0.63 [0.38, 1.04]		
Wang et al 2012	1	37	1	39	0.3%	1.05 [0.07, 16.24]		
Zywiel et al 2009	0	33		33		Not estimable		
Total (95% CI)		2520		2556	100.0%	0.84 [0.73, 0.96]	•	
Total events	284		315			SOL C	65	
Heterogeneity: Chi ² = 2 Test for overall effect: Z	the second se	and the second	0.54 ; $1^2 = 0\%$			6.0	01 0.1 1 10 Favours HR Favours THR	

